Fulgent Genetics (FLGT) Net Equity Issued and Repurchased (2019 - 2021)

Fulgent Genetics has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $13.8 million in Q4 2021.

• Quarterly Net Equity Issued and Repurchased fell 93.21% year-over-year to $13.8 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $89.5 million (down 63.66% YoY) and the FY2021 annual result came in at $89.5 million, down 63.66% from the prior year.
• Net Equity Issued and Repurchased grew to $13.8 million in Q4 2021 per FLGT's latest filing, from -$30000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $203.9 million in Q4 2020 and troughed at -$130000.0 in Q1 2020.
• A 3-year average of $40.4 million and a median of $27.6 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 36859.23% in 2021, down 100.07% in 2021.
• Over 3 years, Net Equity Issued and Repurchased stood at $27.6 million in 2019, then soared by 637.48% to $203.9 million in 2020, then tumbled by 93.21% to $13.8 million in 2021.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $13.8 million, -$30000.0, and $27.9 million for Q4 2021, Q3 2021, and Q2 2021 respectively.